Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Share News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.25
Bid: 44.00
Ask: 45.20
Change: 0.35 (0.79%)
Spread: 1.20 (2.727%)
Open: 45.35
High: 45.95
Low: 45.25
Prev. Close: 44.25
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Novacyt flags possible £3m hit from Covid test regulations change

Tue, 02nd Nov 2021 11:45

(Sharecast News) - Clinical diagnostics specialist Novacyt updated the market on the availability of its Covid-19 tests in the UK on Tuesday, following the implementation of amendments to the UK Health Security Agency's coronavirus test device regulations, or 'CTDA'.
The AIM-traded firm said the mandatory CTDA guidelines would require all suppliers of Covid-19 tests, including both polymerase chain reaction (PCR) and lateral flow tests, to submit data on the tests for a desktop validation if they wished to continue to sell them in the UK.

It said the legislation would not apply or affect any sales outside the UK.

On 20 October, the UK Health Security Agency issued a list of products on the CTDA register that had so far successfully completed such a desktop review and been approved.

A second list, the 'temporary protocol', was also issued, detailing products which could remain on the market while validation was being processed, with an extended deadline from 1 November to 28 February.

Only validated products, or products on the temporary protocol could be sold in the UK after 31 October.

The company said the UK Health Security Agency had committed to continuing its review of submitted tests, and updating the CTDA register accordingly.

"Novacyt submitted 11 products for review on time to meet the original CTDA submission deadline of 1 September," the board said in its statement.

"To date, Novacyt's 'Primerdesign PROmate' Covid-19 test has been named on the temporary protocol," it added, confirming that it encompassed both the PROmate 1 Gene q16 and q32 products.

It said the CTDA had not yet communicated the status of any of the remaining nine products.

"As a result, from 1 November, the company will only be selling the PROmate Covid-19 test in the UK until the UK Health Security Agency completes its review of the additional nine products submitted.

"If no further products are added to the CTDA register, the impact on full year revenues for 2021 will be around £3m."

At 1227 GMT, shares in Novacyt were down 2.46% at 248p.
More News
6 Feb 2024 12:48

Novacyt confirms end of Yourgene Taiwan disposal discussions

(Sharecast News) - Novacyt announced on Tuesday that it had received formal notification from INEX Innovate terminating discussions around the acquisition of Yourgene Health Taiwan.

Read more
2 Jan 2024 08:12

Novacyt taps Steve Gibson for CFO

(Sharecast News) - Biotechnology group Novacyt has appointed Steve Gibson to the role of chief financial officer with immediate effect.

Read more
21 Dec 2023 15:49

Novacyt facing delays in disposal of Yourgene Taiwan

(Sharecast News) - Molecular diagnostics company Novacyt updated the market on the conditional disposal of its laboratory in Taiwan, which it acquired as part of its purchase of Yourgene Health on 8 September.

Read more
3 Jul 2023 09:07

Novacyt to buy Yourgene Health in £16.7m deal

(Sharecast News) - Yourgene Health surged on Monday after it agreed to be bought by Novacyt in a £16.7m deal.

Read more
6 Dec 2022 12:29

UK regulator approves Novacyt Covid-19 test

(Sharecast News) - Shares in clinical diagnostics specialist Novacyt sparked on Tuesday, after the UK regulator approved its latest Covid-19 test.

Read more
15 Jul 2022 08:43

Novacyt's exsig receives UK approval

(Sharecast News) - Clinical diagnostics group Novacyt's exsig Covid-19 Direct Real-Time PCR test has received approval from the UK's Health Security Agency.

Read more
17 Feb 2022 15:38

Novacyt gets another Covid-19 test approved in the UK

(Sharecast News) - Clinical diagnostics company Novacyt announced on Thursday that its 'PROmate' Covid-19 2G Real-Time PCR test had been approved in the UK, under the UK Health Security Agency's coronavirus test device approvals (CTDA) regulations.

Read more
26 Nov 2021 08:02

Novacyt gets UK approval for 'genesig' Covid-19 test

(Sharecast News) - Clinical diagnostics specialist Novacyt announced on Friday thatots 'genesig' Covid-19 real-time PCR test has been approved in the UK.

Read more
30 Sep 2021 09:37

Novacyt launches new 'Winterplex' test, lateral flow tests delayed

(Sharecast News) - Clinical diagnostics specialist Novacyt issued a research and development update on Thursday, including the launch of a new CE-marked 'Winterplex' polymerase chain reaction (PCR) test to diagnose Covid-19, respiratory syncytial virus (RSV) and types of influenza.

Read more
27 Sep 2021 08:15

Novacyt swings to first-half loss amid DHSC dispute

(Sharecast News) - Clinical diagnostics specialist Novacyt reported group consolidated unaudited revenue of £54m in its first half on Monday, down from £63.3m year-on-year, which excluded £40.8m of Department of Health and Social Care (DHSC) revenues, while that contract dispute continued.

Read more
16 Sep 2021 11:05

Novacyt FY revenues potentially 'materially affected' by outcome of DHSC dispute

(Sharecast News) - Biotechnology company Novacyt warned on first-half revenues on Thursday as a result of its ongoing dispute with the US Department of Health and Social Care.

Read more
18 Aug 2021 10:12

First half revenues up more than 50pc for Novacyt

(Sharecast News) - Novacyt said in an update on Wednesday that unaudited revenue in its first half was ahead more than 50% year-on-year, at £94.7m.

Read more
29 Jul 2021 15:31

Novacyt appoints David Allmond as new chief executive

(Sharecast News) - Clinical diagnostics specialist Novacyt announced the appointment of David Allmond as its new chief executive officer and a member of its board on Thursday, effective from 18 October.

Read more
29 Jun 2021 09:03

Novacyt launches two new rapid Covid-19 test products

(Sharecast News) - Clinical diagnostics specialist Novacyt announced the planned launch of two 'PathFlow' Covid-19 antigen lateral flow tests on Tuesday, to strengthen its Covid-19 portfolio and to pursue significant new market opportunities, particularly in point-of-care settings.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.